Selexipag

FDA Drug Profile — Selexipag, UPTRAVI, UPTRAVI Titration Pack, Selexipag TITRATION PACK

Selexipag is listed in the FDA National Drug Code directory with 76 NDC codes, marketed under brand names including Selexipag, UPTRAVI, UPTRAVI Titration Pack. Available dosage forms: powder, tablet, film coated, tablet, coated, kit, injection, powder, for solution.

Drug details

Generic Name
Selexipag
Brand Names
Selexipag, UPTRAVI, UPTRAVI Titration Pack, Selexipag TITRATION PACK
Application Number
ANDA214302
Sponsor
Apicore Pharmaceuticals Private Limited
NDC Codes
76
Dosage Forms
POWDER, TABLET, FILM COATED, TABLET, COATED, KIT, INJECTION, POWDER, FOR SOLUTION, CAPSULE
Routes
ORAL, INTRAVENOUS
Active Ingredients
SELEXIPAG

Indications and Usage

1 INDICATIONS AND USAGE UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I): In adults to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 ) In pediatric patients aged 2 years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 ) 1.1 Pulmonary Arterial Hypertension Adult Patients UPTRAVI is indicated for the treatment of pulmonary arterial hypertension in adults (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness of UPTRAVI tablets was established in a long-term study in adult PAH patients with WHO Functional Class II–III symptoms. Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), PAH associated with congenital heart disease with repaired shunts (10%) [see Clinical Studies (14.1) ] . Pediatric Patients UPTRAVI is indicated for the treatment of PAH (WHO Group I) in pediatric patients aged two years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.